About the Authors

Rodney R. Dietert is Professor of Immunotoxicology at Cornell University, Ithaca, NY whose interests focus on the prevention of chronic diseases via patterns that first emerge in children. Dietert’s recent books include Strategies For Protecting Your Child’s Immune System (World Scientific, Singapore, Hackensack, NJ, 2010) and Immunotoxicity Testing (as Editor) (Springer, NY, 2010). He previously directed Cornell’s Program on Breast Cancer and Environmental Risk Factors and the Institute for Comparative and Environmental Toxicology and served as a Senior Fellow in Cornell’s Center for the Environment. Dietert recently served on panels for the Institute of Medicine (Agent Orange), the WHO (Immunotoxicology Risk Assessment), and the EPA (trichloroethylene).

Robert W. Luebke is an immunotoxicologist with the US Environmental Protection Agency in Research Triangle Park, NC whose research is focused on the consequences of exposure to environmental chemicals on immune system homeostasis and resistance to infectious disease, and the development of alternative testing methods for high-throughput screening of chemicals for immune system toxicity. He has authored numerous book chapters on immunotoxicology and immunotoxicology methods and served as senior editor of the third edition of Immunotoxicology and Immunopharmacology (CRC Press, Boca Raton, FL, 2007). Recent service activities include membership on the core writing group for the WHO Harmonized Immunotoxicity Risk Assessment Guidelines and the Organization for Economic Cooperation and Development’s Technical Guidance 443, the Extended One-Generation Reproductive Toxicity Study.
Index

A
Acquired immunodeficiency syndrome (AIDS), 351
Acrylates and epoxys, 112
Acute otitis media (AOM), 393–394
Acute respiratory distress syndrome (ARDS)
  AhR activation, 331
  epithelial injury, 330
  IL-22 expression, 332
  lipopolysaccharide, 331
  neutrophils, 331
  pulmonary edema, 332
  systemic inflammatory response syndrome, 330
Adaptive immune system
cells
  antigen presenting cells, 6–7
  B lymphocytes, 7
  T lymphocytes, 7
recognition and activation
  antibodies, 10
  antigen presentation, 10
  antigens, 9
  B cell activation, 11–12
  T cell activation, 10–11
tissues
  bone marrow, 8
  lymph nodes, 9
  mucosal-associated lymphoid tissue, 9
  spleen, 8
  thymus, 8
Adenosine triphosphate (ATP), 226
Adenovirus, 222
Affective spectrum disorder, 348
Allergens, food allergy, 132
  complement pathway activation, 133–134
eye white proteins, 133
  gastric acidity, 133
  peanut and tree nut allergens, 133
  physicochemical properties, 133
Allergic contact dermatitis (ACD)
  acrylates and epoxys, 112
  cetostearyl alcohol, 112
  contact allergens
    major, 108–110
    minor, 110–111
  epidemiology, 113–114
  experimental human data, 114
  fragrances, 111–112
  hair dyes, 111
  isopropyl myristate, 112
  preservatives, 111
  skin sensitization
    bioavailability, 105–106
    cell-based assays, 121
    chemical allergens, 105
    keratinocytes and extracellular matrix, 107–108
    non-animal approach, 121
    Tc cells, contact hypersensitivity, 107
    T lymphocyte activation, 106–107
Allergy. See also Asthma and respiratory allergic disease
  adaptive immune system, 67
  hygiene hypothesis, 69–70
  hypersensitivity reactions
Allergy. See also Asthma and respiratory allergic disease (cont.)

type I hypersensitivity reactions, 12–13

type II, 13

type III, 13

type IV, 13

innate immunity

cell death-associated molecules, 68
damage-associated molecular matters, 68
danger theory, 68
infectious agents, 67
PRR, 68–69

sensor and effector components, 67
toll-like receptor, 69
toll-like receptor signaling, TLR4

Asp299Gly minor allele expression, 74
dendritic cells and, 72
endotoxin, 73

environmental challenges, 70
functions, 70–71
LPS, 71

mouse models, 73
PRRs, 72

rural and urban environment pollutants, 71–72
TRIF-mediated signaling, 71

Alzheimer’s disease (AD)
amyloid plaques, 218, 231
β-Amyloid deposition, 239–240
BBB, 236

genetic susceptibility, 237

immune system

complement system activation, 234–235
neuroinflammation, 231–234

T Lymphocytes, 235–236
infectious agents, 238–239
inherited-dominant mutations, 217
neurofibillary tangles, 218
progressive dementia, 230
risk factors, 237–238

Amyloid precursor protein (APP), 217

Antibody-mediated autoimmune disease, 13–14

Anti-citrullinated peptide autoantibodies (ACPA), RA

ACPA-positive RA, 185
future aspects, 186
MHC class II molecules, 184–185
PAD expression, 185–186
pathogenic, 186

Antihypertensive therapies, 273

Antiphospholipid syndrome (APS), 256

Aryl hydrocarbon receptor (AhR) signaling

ARDS (see Acute respiratory distress syndrome (ARDS))

COPD (see Chronic obstructive pulmonary disease (COPD))

IL-22 expression (see Interleukin 22 (IL-22))

IPF (see Idiopathic pulmonary fibrosis (IPF))

ligand-dependent regulation

basic helix-loop-helix, 317
benzo(a) pyrene (BaP), 316
chromatin remodeling, 318
cytosol, 317
dioxin, 315

DRE sequences, 319

TGFβ, 319

tryptophan derivatives, 316

Sarcoidosis (see Sarcoidosis)
silicosis (see Silicosis)

Asthma and respiratory allergic disease.

See also Allergy

air pollution risk, 53

airway epithelium, 65

allergic airway inflammation
dendritic cell-mediated regulation, 60, 61
eosinophils, 60
hypoxia-inducible factor, 58–59
lung remodeling, 59–60

mast cells, 60

atopy, 57–58

IgE, 61–63

inflammatory mediators, 63

localized atopic responses, 60

systemic atopic responses, 60

tissue remodeling process, 63

clinical characteristics, 53

economic burden, 54

epigenetics
cellular functions, 86–87
histone deacetylation, 87
histone modification, 87
microRNAs, 87

epithelial barrier, 65

external environment sensing and dendritic cell

CD4+ helper T cells, 74

cell surface chemokine receptors, 75
diesel-enriched PM, 76, 78–79
environmental APM, 76, 78–79

outdoor air pollutants, 75

protease-dependent pro-Th2 allergens, 78
TLR expression, 77
trans-epithelial interacting cellular network, 77–78
gene–environment interactions, 83–84
genetic and familial factors, 54–55
genetic susceptibility
  *DENND1B*, 83
genome-wide association studies, 82
  *IL-33* 82, 83
  *IL2RB*, 83
  *RAD50*, 83
  *SMAD3*, 82–83
gut microbiome, 88–89
  *IgG4*, 64–65
  incidence, 53
  inflammesome, 79–80
  lung sensitization, 80–81
  mortality and morbidity, 54
  multiethnic genome wide association studies, 84–86
  National Cooperative Inner-City Asthma Study, 54
pattern recognition receptors, 52
phenotypes, 56
prevalence, 56
ROS-induced injury, 65
  skin barrier impairments, 81
structural changes, 65–67
Autism spectrum disorders (ASDs)
  adaptive immune abnormalities, 259–260
  altered cytokine production, 257–258
autoantibodies, 260–261
immune dysfunction, historical links of, 254
immunogenetics, 262
innate immune abnormalities, 258–259
maternal antibodies, 256–257
maternal immune activation, 254–256
mucosal immunity, 261–262
Autoimmune thyroiditis
  breast cancer, 424
  comorbidities, 425
  depression, 424
  Grave’s disease, 423
  Hashimoto’s disease, 423
  hearing loss, 424
Autoimmunity and heart disease
  RA, 282–283
  SLE, 281–282
B
  *Bacille Calmette-Guerin* (BCG), 350
  Benzene metabolites, 409
Bleomycin, 326
*Bordetella pertussis* toxin, 220
Borna disease virus (BDV), 352
*Borrelia burgdorferi*, 238
Buehler test, 17

C
  *Campylobacter* spp., 302
Celiac disease (CED)
  chronic disease comorbidities
    extra-gastrointestinal health risks, 298
    GI tract cancers, 299
    miscarriage, 300
    psychiatric symptoms, 299
    restless leg syndrome, 300
    sarcoidosis, 298
    T cell lymphomas, 299
  environmental risk factors, 303–304
vs. IBD, 296–297
Cell-mediated autoimmune disease, 14
Cerebral amyloid angiopathy (CAA), 236
Cetostearyl alcohol, 112
Chemical allergens, 105
Childhood acute leukemia
  aberrant immune modulation
    allergy, 405
    childcare history, 404
    daycare attendance studies, 404
    delayed infection hypothesis, 404
    *Haemophilus influenzae*, 405
    hygiene hypothesis, 405
    IL-10 production, 406
    immunological development, 403
    UKCCS, 405
  adult leukemias, 408–409
  age group, 401
  atomic bomb exposure, 403
  cALL, 400
  cord bloods, 402
  diagnostic imaging, 403
  environmental causes, 409–410
  Fallon cluster, 408
  genetic mutations, 402
  hematopoiesis, 401
  infant leukemias and MLL translocation, 406–407
  pre-B lymphocytic phenotype, 400
  Seascale cluster, 408
  Woburn cluster, 408
  *Chlamydia pneumoniae*, 238
Chronic disease
cancers, 42
Chronic disease (cont.)
chronic disease risk
antibody and T cell effector response, 34–35
pattern recognition receptors, 35
early life environmental conditions, 35–36
environment-immune route
(see Environmentally induced immune dysfunction)
gender-related symptoms, 34
inflammatory diseases, 41–42
malfunctioning target organ, 35
premature death, 33
resident macrophages, 33, 34
risk reduction, 43
societal impact, 36
symptomatic endpoints, 34
tissues and physiological systems, 33–34
Chronic obstructive pulmonary disease (COPD), 299
airway hyperreactivity, 323
α1-antitrypsin deficiencies, 323
bronchodilator, 323
cigarette smoking, 322–323
cytochrome P450 enzymes, 324
genetic susceptibility, 323
immunopathogenic process, 325
neutrophilia and tissue remodeling, 325
oxidants and antioxidants, 323
pattern recognition receptors, 324
Claudin-1, 81
Clostridium difficile, 302
Cognitive behavior therapy, 369
Collagen-induced arthritis mouse model, 176
Common acute lymphocytic leukemia (cALL), 400
Coronary artery disease (CAD), 359
Corticotropin-releasing hormone (CRH), 361
Coxackie virus, 222
Crohn’s disease (CD), 225
Cutaneous allergies. See Allergic contact dermatitis
Cyclic adenosine monophosphate (cAMP), 226
Cytokine hypothesis, 349–350

D
Delayed-type hypersensitivity (DTH) reactions, 13
Developmental immunotoxicology, 24–26
Dichlorodiphenyldichloroethylene (DDE), 392
Dioxins, 316
Docosahexaenoic (DHA), 362

E
Eicosapentaenoic (EPA), 362
Electroconvulsive therapy, 367
Environmentally induced immune dysfunction
cyclosporine A, 39–40
differential risk
chemicals and drugs, age-based comparison, 36
cytokine and immune cell receptor expression, 36–37
sexual dimorphism, 37
variables, 36
environmental risk factors
categories of, 38
childhood asthma, 40–41
preventive measures, 41
secondary bacterial infections, 41
environmental tobacco smoke
allergic diseases, 38
immunotoxins, 39
lead, 39
herbicide atrazine, 39
immune risk factor interaction, 41
Environmental toxicants
acute otitis media, 393–394
immunotoxicants, 390
lower airway infection
DDE, 393
organochlorines, 392
polychlorinated dibenzo-p-dioxins, 392
welding, 393
Yusho (oil disease), 392
PCB, 391
T lymphocytes, 390
viral infections, 394–395
Eosinophilic myocarditis, 278
Epitope spreading, 223
Epstein–Barr virus (EBV)
rheumatoid arthritis, 180
systemic lupus erythematosus, 200–201
European Medicines Evaluation Agency (EMEA), 21
Experimental autoimmune encephalomyelitis (EAE), 219

F
Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), 431
Filaggrin, 81
Food allergy
allergens, 132
complement pathway activation, 133–134
Index

egg white proteins, 133
gastric acidity, 133
peanut and tree nut allergens, 133
physicochemical properties, 133
dermal and respiratory sensitization
allergenic protein, 136–137
flaggrin deficiency, 136
inhalation exposure, 136
latex allergy, 135
diet and lifestyle
fruit and vegetable consumption, 137
hygiene hypothesis, 138
omega-3 polyunsaturated fatty acid, 137
omega-6 polyunsaturated fatty acid, 137
vitamin D deficiency, 137–138
environmental insult
air pollution, 138–139
oxidative stress, 139
pesticides, 139–140
Th2-type responses, 140
food intolerance, 129
genetics, 134–135
hypersensitivity reactions
IgE-mediated response, 129–130
IgG antibody, 130
type IV, 130–131
oral tolerance
in animal models, 131–132
factors affecting, 131
gut microbes, 132
intestinal health, 132
transcytosis, 131
prenatal and early life factors, 135
Fragrances, 111–112
Fulminant myocarditis, 278

G
Gastrointestinal (GI) symptoms, 261
Giant cell myocarditis (GCM), 278
Glatiramer acetate (GA), 230
Glial fibrillary acidic protein (GFAP), 260
Guinea pig maximization test (GPMT), 17

H
Haemophilus influenzae, 405
Hair dyes, 111
Heat shock proteins (HSPs), 177–178
Helicobacter pylori, 238, 358
Hemochromatosis (HH), 180
Hepatitis B (HBV), 351
Hepatitis C (HCV), 351
Herpes simplex virus (HSV), 222
Hexachlorobenzene (HCH), 394
HLA genes, 262
Host resistance assays, 16–17
Human herpes virus 6 (HHV6)
CNS barriers, 224–225
dysregulated inflammation, 225
genetic and environmental factors, MS pathogenesis, 224
neonatal inflammation, 225
purinergic signaling (see Purinergic signaling)
Human immunodeficiency virus (HIV), 351
Human repeated insult patch test (HRIPT), 119
Hypothalamic-pituitary-adrenal (HPA) axis dysregulation, 183
Hypoxia-inducible factor (HIF), 58–59

I
Idiopathic pulmonary fibrosis (IPF)
bleomycin, 326
chronic lung disease, 325
collagen deposition, 327
usual interstitial pneumonia, 326
Immune-based chronic disease
autoimmune thyroiditis, 423–425
digital/electronic health scorecard, 435
frailty
aging process, 427
chronic low-grade inflammation, 426
comorbid relationships, 426
end-stage condition, 425
environmental tobacco smoke, 426
geriatric syndrome, 425
inflammatory dysfunction
immune activation-inflammation, 427
isolation/withdrawal, 428
suicide risk, 428
psoriasis, 422–423
safety testing system
asthma and autism, 431
immunotoxicity, 431
predictive biomarkers, 431
priority disease-driven model, 432
toll-like receptors, 432
strategic prevention and intervention, 429–430
therapeutic interventions, 434–435
Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, 221
Immune system
adaptive (see Adaptive immune system)
allergic hypersensitivity reactions, 12–13
autoimmunity, 13–14
immune regulation and tolerance, 12
innate (see Innate immune system)

Immunotoxicity
emerging issues, 23
developmental immunotoxicology, 24–26
in vitro immunotoxicity testing, 24, 27
hypersensitivity assays
guinea pig skin sensitization model, 17
local lymph node assay, 17–18

immunosuppression assays
host resistance assays, 16–17
lymphoproliferative assays, 15
natural killer cell assay, 16
plaque forming cell assay, 15–16
popliteal lymph node assay, 18

testing and risk assessment guidelines
European Medicines Evaluation Agency, 21
International Council on Harmonization, 21–23
International Program on Chemical Safety, 23
Organization for Economic Cooperation and Development, 19
US Environmental Protection Agency, 19–20
US Food and Drug Administration, 21

Infectious mononucleosis, 223. See also Epstein–Barr virus (EBV)

Inflammasome, 79–80

Inflammatory bowel disease (IBD)
chronic disease comorbidities, 297–298
Crohn’s disease vs. ulcerative colitis, 293–294
differential prevalences and susceptibilities, 294
environmental risk factors
antibiotics/analgesics, 303
Caesarian delivery, 302
eyear-life infection, 302
microbial diversity, 303

immune dysfunction
acute inflammation, 296
Caspase 8, 296
colonic Tregs, 295
dysplastic reticulum (ER) stress, 295
GI tract microbiota, 295
NOD-2 signaling, 296

Inflammatory heart disease
atherosclerosis
animal models, 273
antihypertensive therapies, 273
tobacco smoke, 276

Inflammation
acute
allergic inflammatory reactions, 12
autoimmune diseases, 276
atherosclerosis
chemotherapeutic agents, 274
chemoprevention, 274
hypertension, 272
idiopathic giant cell myocarditis, 275
myocardial infarction, 272

K
Kynurenine, 364

L
Lipid transfer proteins (LTPs), 136
Lipopolysaccharide (LPS), 224
Listeria monocytogenes, 391
Local lymph node assay (LLNA), 17–18, 117–119
Lymphocytic myocarditis, 278

M
Macrophages, 5
Macrophagic myofasciitis (MMF), 202
Major depressive disorder (MDD)
cytokines effects
  hypothalamic-pituitary-adrenal axis, 365
  indoleamine 2,3-dioxygenase, 363–364
  neurotransmitters, 365
  serotonin availability and metabolism, 364–365
epidemiology and clinical manifestations
  brain dysfunction, 348–349
  depression, biochemistry of, 348–349
  diagnosis, 347–348
  genetics and familial risk, 348
  prevalence, 347
immune alteration, 362
immune status and depression, 352–353
immuno-compromising chemicals, 357–358
impaired immune function
  autoimmune diseases, 359
  cancer, 358–359
  cardiovascular disease, 359
  chronic pain, 360
  menstrual cycle, 360
  omega-3 deficiency, 362
  PPD, 360–361
infection-defense hypothesis
  bidirectional process, 371
  immune vulnerability, 370
  neuroendocrine factors, 371
  sickness behavior, 370
infectious diseases and depression
  acute/subacute infections, 350
  chronic infections, 350–351
  live-virus vaccines, 351–352
  psychotropic effects, 352
  insomnia, 354–355
mood interventions and alterations
  antidepressants and immune function, 366–367
  electroconvulsive therapy, 367
  ketamine, 368–369
  physical activity, 367–368
  psychosocial interventions, 369
  positive mood and immune function, 369
  proinflammatory cytokines, 349–350
  psychological stress, 354
  seasonal risk factors (see Seasonal affective disorder (SAD))
sickness behavior and depression, 349
Major histocompatibility complex (MHC), 219, 262
Melatonin, 356
Microglial cells, 219
Mindfulness training, 369
Molecular mimicry mechanism
  rheumatoid arthritis, 178
  systemic lupus erythematosus, 199
Monoamine hypothesis, 348
Mucosal-associated lymphoid tissue (MALT), 9
Multiple sclerosis (MS)
  adenosine, 227–228
  animal models, 219–220
  ATP, 227
  autoimmunity, 219
  cigarette smoking, 228
  CNS antigens, 219
demyelination and axonal injury, 217
environmental factors
  EBV, 223
  HHV6, 223–227
  infection hypothesis, 222–223
  genetic susceptibility, 221–222
  immune regulatory factors, 221
  immunopathogenesis, 218
  marked disability, 217
  microglial cells, 219
  myelin antigens, 218, 219
  relapsing/remitting course, 217
  sex hormones, 228
  therapy, 228–230
  T Regulatory Cells (Treg), 220–221
  ultraviolet light, 228
Myelin basic protein (MBP), 260

N
Natural killer cell activity (NKCA), 5, 16, 366
Neonatal lupus syndrome, 256
Neurofibrillary tangles (NFTs), 218
Neurological disease, 223. See also Human herpes virus 6 (HHV6)
Neuropilin-1 (Nrp1), 221
Neutrophils, 5
Nitric oxide (NO), 218
NOD-like-receptor-protein-3 (NLRP3) inflammasome, 79–80
Nonallergic (intrinsic) asthma
  BAL fluid, 56
Nonallergic (intrinsic) asthma (cont.)
cytokine profile, bronchial mucosa, 56
irritant-induced asthma, 56
macrophages, 56–57
serum IgE, 63–64
vs. allergic, 57
Noncommunicable diseases (NCDs), 420
Non-steroidal anti-inflammatory drugs (NSAIDs), 233
Nucleotide-binding oligomerization domain 2 (NOD-2), 296

O
Omega-3 deficiency, 362
Oral tolerance
in animal models, 131–132
factors affecting, 131
gut microbes, 132
intestinal health, 132
transcytosis, 131
Organophosphates (OP), 357
Oxidized low-density lipoprotein (OxLDL), 273

P
Particulate matter (PM), 274
Pathogen-associated molecular patterns (PAMPs), 6
Pattern recognition receptors (PRRs), 6, 35, 52
Peptidylarginine deiminase (PAD), 185–186
Pericarditis, 283
Peripheral blood mononuclear cells (PBMCs), 238, 261
Peripheral tolerance mechanism, 219
Plaque forming cell assay, 15–16
Plasmodium berghei, 201
Plasmodium yoelii, 391
Polychlorinated biphenyls (PCBs), 390
Polycyclic aromatic hydrocarbons (PAHs), 254
Proliferating cell nuclear antigen (PCNA), 18
Postpartum depression (PPD), 360–361
Premenstrual dysphoric disorder (PMDD), 360
Premenstrual syndrome (PMS), 360
Prion-related protein (PRNP) gene, 86
Psoriasis
alcohol, 422
comorbid diseases and conditions, 424
CVD-associated mortality, 423
subclinical atherosclerosis, 423
systemic comorbidities, 422
tobacco smoke, 422
Psychological stress, 354
Purinergic signaling
CNS damage, 227
MS pathogenesis, 226
peripheral immune response, 226–227
P2X7 receptor, 227
Pyrin and HIN domain family member 1 (PYHN1), 86

Q
Quinolinic (QUIN) acid, 364

R
Restless leg syndrome, 300
Rheumatoid arthritis (RA), 274
anti-citrullinated peptide autoantibodies
ACPA-positive RA, 185
future aspects, 186
MHC class II molecules, 184–185
PAD expression, 185–186
pathogenic, 186
etiology
bystander/adjuvant effect, 179–180
dietary risk factors, 181–183
epigenetic regulation, 176–177
infections, 177–178
inhalation toxicology, 183–184
oral contraception, 183
oxidative stress, 180–181
stress and hormones, 183
immune dysfunction
anticitrullinated peptide antibodies, 175–176
Fc-receptor-mediated cytotoxicity, 175
inflammatory cytokines, 174
posttranslational modifications, 175
T and B cells, 174–175
prevalence
genetics vs. environment, 173–174
incidence, 173
twin concordance studies, 173–174
Rhino virus, 222

S
Sarcoidosis
bronchoalveolar lavage, 329
IL-22, 330
lung disease, 329
microbial organisms, 328
noninfectious environmental agents, 328
Seasonal affective disorder (SAD)
cold stress, 355
melatonin, 356
vitamin D, 356–357
Selective serotonin reuptake inhibitors (SSRIs), 366
Serotonin transporter (SERT), 348
Silicosis
  acute inflammation, 333
  AhR signaling pathway, 333
  alveolar macrophages, 332
  bone marrow-derived macrophages, 333
  IL-1β secretion, 332
Skin sensitization
  bioavailability, 105–106
  cell-based assays, 121
  chemical allergens, 105
  keratinocytes and extracellular matrix, 107–108
  non-animal approach, 121
  Tc cells, contact hypersensitivity, 107
  T lymphocyte activation, 106–107
Skin sensitizers
  hazard characterization, 116
  hazard identification, 115–116
  potency assessment, 116
  skin sensitization risk assessment
    human repeated insult patch test, 119
    LLNA, 117–119
    local lymph node assay, 117–119
    quantitative risk assessment, 119–120
Structured Clinical Interview for DSM disorders (SCID), 358
Systemic lupus erythematosus (SLE), 256
  chemical exposure and risk
    agricultural pesticides, 197–198
    mercury, 196
    phthalate, 196
    silica dusts, 195
    trichloroethylene, 197
  cigarette smoking, 198–199
drug-induced lupus erythematosus
  anti-TNF-α-induced SLE, 205
  definition, 203
  DISLE, 203–204
  drug-induced CCLE, 205
  drug-induced SCLE, 204–205
  incidence, 203
  interferon, 205
  mechanisms, 205
etiopathogenesis of, 194
future aspects, 208
infections
  bystander activation, 200
  CMV and parvovirus B19, 201
  epitope spreading, 199
  Epstein–Barr virus, 200–201
  hygiene hypothesis, 201
  molecular mimicry, 199
  rubella and mumps infection, 201
  viral and bacterial super antigens, 200
  viral persistence and polyclonal activation, 200
  prevention of, 208
  ultra violet radiation, 206–207
  vaccines
    autoimmunity, 201–202
    hepatitis-B immunization, 202–203
    temporal and causal associations, 201

T
Taiwan National Health Insurance claims database, 423
T cell-dependent antibody response (TDAR), 15–16
Tier testing, 18–20
TIR domain-containing adaptor protein (TIRAP), 71
TNF-receptor-associated factor 6 (TRAF6), 71
Toll-like receptor (TLR), 179–180
Toxoplasma gondii, 239, 352
T regulatory (Treg) cells, 12
Treponema pallidum, 238
Tumor necrosis factor (TNF)-α, 218
Type 1 diabetes (T1D)
  autoimmune aetiology, 154
  cell types, 156
    B cells, 157
    CD8+ T cells, 155–156
    cytokine-mediated destruction, 155
    dendritic cells, 155
    macrophages, 155
  complications, 154
  early diagnosis and therapy, 162–163
  and environment, 160–162
  genetics, 158–159
  immune deficiencies
    diabetes-prone BB rat, 157
    diabetes-resistant subline of BB rats, 157
    lymphopenia, NOD mice, 157–158
    NKT cells, 158

U
Ulcerative colitis (UC), 225
United Kingdom Childhood Cancer Study (UKCCS), 405

V
Vasopressin (AVP), 365

W
West Nile virus (WNV), 350